基于多参数MRI影像组学鉴别乳腺癌HER2过表达、低表达与零表达状态
回顾性纳入两家机构771例乳腺癌患者,提取T2WI-FS、DWI、ADC和DCE的多参数MRI影像组学特征,构建三个模型分别鉴别HER2过表达、低表达和零表达状态;外部验证集AUC分别为0.725、0.782和0.813,提示影像组学模型可能术前预测HER2状态。
要点
- 多参数MRI影像组学模型可术前鉴别HER2过表达、低表达与零表达,外部验证AUC为0.725、0.782、0.813。
- HER2零表达vs其他的鉴别效能最高,外部验证AUC为0.813。
- DWI、ADC和DCE是构建三个模型的主要序列来源。
核心结论
- 多参数MRI影像组学模型可能术前预测乳腺癌患者的HER2状态。
- 基于MRI的影像组学模型可无创识别乳腺癌HER2表达状态的新三分类,有助于HER2靶向治疗的决策。
研究设计与样本
- 回顾性研究,共纳入两家机构771例乳腺癌患者。
- 机构I的581例分为训练集407例和独立验证集174例;机构II的190例构成外部验证集。
- 所有患者根据病理检查分为HER2过表达、HER2低表达和HER2零表达组。
- 提取T2WI-FS、DWI、ADC和DCE的多参数MRI影像组学特征,在训练集中用LASSO回归筛选特征。
- 基于筛选特征构建三个模型:HER2过表达vs其他、HER2低表达vs其他、HER2零表达vs其他,用AUC评价模型效能。
关键影像表现/征象
- HER2过表达、低表达和零表达乳腺癌的MRI影像组学特征存在显著差异。
诊断标准与关键数值
- HER2过表达vs其他模型:训练集、独立验证集和外部验证集的AUC分别为0.809、0.737和0.725。
- HER2低表达vs其他模型:训练集、独立验证集和外部验证集的AUC分别为0.779、0.778和0.782。
- HER2零表达vs其他模型:训练集、独立验证集和外部验证集的AUC分别为0.889、0.867和0.813。
- HER2过表达vs其他模型纳入来自DWI、ADC和DCE的11个影像组学特征。
- HER2低表达vs其他模型纳入来自DWI的1个影像组学特征;HER2零表达vs其他模型纳入来自DWI、ADC和DCE的17个影像组学特征。
临床应用与阅片要点
- 术前可基于多参数MRI影像组学评估乳腺癌HER2表达状态,以辅助筛选抗HER2治疗的潜在候选者。
- 影像组学特征主要来自DWI、ADC和DCE序列,阅片时需关注这些序列的图像质量与特征提取的一致性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To explore the performance of multiparametric MRI-based radiomics in discriminating different human epidermal growth factor receptor 2 (HER2) expressing statuses (i.e., HER2-overexpressing, HER2-low-expressing, and HER2-zero-expressing) in breast cancer.
METHODS: A total of 771 breast cancer patients from two institutions were retrospectively studied. Five-hundred-eighty-one patients from Institution I were divided into a training dataset (n1 = 407) and an independent validation dataset (n1 = 174); 190 patients from Institution II formed the external validation dataset. All patients were categorized into HER2-overexpressing, HER2-low-expressing, and HER2-zero-expressing groups based on pathologic examination. Multiparametric (including T2-weighted imaging with fat suppression [T2WI-FS], diffusion-weighted imaging [DWI], apparent diffusion coefficient [ADC], and dynamic contrast-enhanced [DCE]) MRI-based radiomics features were extracted and then selected from the training dataset using the least absolute shrinkage and selection operator (LASSO) regression. Three predictive models to discriminate HER2-overexpressing vs. others, HER2-low expressing vs. others, and HER2-zero-expressing vs. others were developed based on the selected features. The model performance was evaluated using the area under the receiver operating characteristic curve (AUC).
RESULTS: Eleven radiomics features from DWI, ADC, and DCE; one radiomics feature from DWI; and 17 radiomics features from DWI, ADC, and DCE were selected to build three predictive models, respectively. In training, independent validation, and external validation datasets, radiomics models achieved AUCs of 0.809, 0.737, and 0.725 in differentiating HER2-overexpressing from others; 0.779, 0.778, and 0.782 in differentiating HER2-low-expressing from others; and 0.889, 0.867, and 0.813 in differentiating HER2-zero-expressing from others, respectively.
CONCLUSIONS: Multiparametric MRI-based radiomics model may preoperatively predict HER2 statuses in breast cancer patients.
CLINICAL RELEVANCE STATEMENT: The MRI-based radiomics models could be used to noninvasively identify the new three-classification of HER2 expressing status in breast cancer, which is helpful to the decision-making for HER2-target therapies.
KEY POINTS: • Detecting HER2-overexpressing, HER2-low-expressing, and HER2-zero-expressing status in breast cancer patients is crucial for determining candidates for anti-HER2 therapy. • Radiomics features from multiparametric MRI significantly differed among HER2-overexpressing, HER2-low expressing, and HER2-zero-expressing breast cancers. • Multiparametric MRI-based radiomics could preoperatively evaluate three different HER2-expressing statuses and help to determine potential candidates for anti-HER2 therapy in breast cancer patients.
引用
- Zheng S, Yang Z, Du G, et al. Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics. Eur Radiol. 2024. PMID: 38363315. doi:10.1007/s00330-024-10641-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。